beta
IA Trial Radar

Mostrando ensayos clínicos realizados em: Greater London.

Puedo ayudarle a encontrar ensayos clínicos en ubicaciones específicas y ofrecerle perspectivas clínicas sobre condiciones de salud y tratamientos.

Con el modo avanzado, acceda a potentes herramientas de preselección, visualizaciones interactivas y alertas por correo electrónico personalizadas sobre actualizaciones de ensayos.

Nuestra herramienta de búsqueda solo admite inglés. Para búsquedas y discusiones en otros idiomas, use la IA Trial Radar o seleccione los filtros de condición médica y ubicación a continuación.
67 resultados
Mostrando los 50 primeros
 
Estado (Por defecto)
Aún No Recluta, Reclutando, Activo, No Reclutando
×
 
Ubicaciones
Greater London
×
 
Sexo biológico
Todos
×
 
Tipo de estudio
Intervencionista
×
 
Tipo
Biológico
×
 
Título del estudio
Estado
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years NCT06735248
Reclutando
First-in-Human Study of ICT01 in Patients With Advanced Cancer (EVICTION) NCT04243499
Activo, no reclutando
Nivolumab in Combination With Chemo-Immunotherapy for the Treatment of Newly Diagnosed Primary Mediastinal B-Cell Lymphoma NCT04759586
Activo, no reclutando
MAGNITUDE: A Phase 3 Study of NTLA-2001 in Participants With Transthyretin Amyloidosis With Cardiomyopathy (ATTR-CM) NCT06128629
Reclutando
Testing Sacituzumab Govitecan Therapy in Patients With HER2-Negative Breast Cancer and Brain Metastases NCT04647916
Activo, no reclutando
A Clinical Study of Calderasib (MK-1084) With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) NCT06997497
Reclutando
Comparison of Standard of Care Treatment With a Triplet Combination of Targeted Immunotherapeutic Agents NCT04739800
Activo, no reclutandoResultados publicados
Long-Term PF-06651600 for the Treatment of Alopecia Areata (ALLEGRO-LT) NCT04006457
Activo, no reclutandoResultados publicados
EA2176: Phase 3 Clinical Trial of Carboplatin and Paclitaxel +/- Nivolumab in Metastatic Anal Cancer Patients NCT04444921
Activo, no reclutando
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations NCT06998940
Reclutando
Prueba de la efectividad de dos fármacos de inmunoterapia (Nivolumab e Ipilimumab) con un fármaco dirigido anticancerígeno (Cabozantinib) para tumores genitourinarios raros NCT03866382
Reclutando
Pivotal 2 Study of RGX-314 Gene Therapy in Participants With nAMD (ASCENT) NCT05407636
Reclutando
A Study Testing the Effect of Immunotherapy (Ipilimumab and Nivolumab) in Patients With Recurrent Glioma With Elevated Mutational Burden NCT04145115
Activo, no reclutando
Comparing the New Anti-cancer Drug Eribulin With Chemotherapy Against the Usual Chemotherapy Alone in Metastatic Urothelial Cancer NCT04579224
Activo, no reclutando
Using Biomarkers to Help Guide Safe Immunotherapy Discontinuation in Patients With Unresectable Stage IIIB-IV Melanoma, The PET-Stop Trial NCT04462406
Activo, no reclutando
Gemcitabine and Cisplatin Without Cystectomy for Patients With Muscle Invasive Bladder Urothelial Cancer and Select Genetic Alterations NCT03609216
Reclutando
Estudio de Pembrolizumab (MK-3475) frente a placebo en participantes con carcinoma esofágico que reciben quimioterapia y radioterapia (MK-3475-975/KEYNOTE-975) NCT04210115
Activo, no reclutando
Shorter Chemo-Immunotherapy Without Anthracycline Drugs for Early-Stage Triple Negative Breast Cancer NCT05929768
Reclutando
Testing the Addition of Pembrolizumab, an Immunotherapy Cancer Drug to Olaparib Alone as Therapy for Patients With Pancreatic Cancer That Has Spread With Inherited BRCA Mutations NCT04548752
Activo, no reclutando
Ramucirumab and Paclitaxel or FOLFIRI in Advanced Small Bowel Cancers NCT04205968
Reclutando
Testing Immunotherapy Versus Observation in Patients With HPV Throat Cancer NCT03811015
Activo, no reclutando
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone NCT03660826
Activo, no reclutandoResultados publicados
Prueba del uso de terapia combinada en pacientes adultos con mieloma múltiple recién diagnosticado, el ensayo equate NCT04566328
Reclutando
A Study to Compare Treatments for a Type of Kidney Cancer Called TFE/Translocation Renal Cell Carcinoma (tRCC) NCT03595124
Activo, no reclutandoResultados publicados
Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease NCT03516279
Activo, no reclutando
Osimertinib With or Without Bevacizumab as Initial Treatment for Patients With EGFR-Mutant Lung Cancer NCT04181060
Reclutando
Testing the Addition of an Antibody to Standard Chemoradiation Followed by the Antibody for One Year to Standard Chemoradiation Followed by One Year of the Antibody in Patients With Unresectable Stage III Non-Small Cell Lung Cancer NCT04092283
Activo, no reclutando
Testing the Addition of the Pill Chemotherapy, Cabozantinib, to the Standard Immune Therapy Nivolumab Compared to Standard Chemotherapy for Non-small Cell Lung Cancer NCT04310007
Activo, no reclutando
ShortStop-HER2: 12 Months vs. 6 Months of HER2-targeted Medications for People With HER2+ Breast Cancer Who Had a Pathologic Complete Response After Chemotherapy Plus Trastuzumab NCT06876714
Reclutando
Testing Early Treatment for Patients With High-Risk Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Leukemia (SLL), EVOLVE CLL/SLL Study NCT04269902
Reclutando
Pembrolizumab in Treating Patients With Desmoplastic Melanoma That Can or Cannot Be Removed by Surgery NCT02775851
Activo, no reclutandoResultados publicados
mFOLFIRINOX Versus mFOLFOX With or Without Nivolumab for the Treatment of Advanced, Unresectable, or Metastatic HER2 Negative Esophageal, Gastroesophageal Junction, and Gastric Adenocarcinoma NCT05677490
Reclutando
Testing the Addition of a New Anti-cancer Drug, Venetoclax, to Usual Chemotherapy for High Grade B-cell Lymphomas NCT03984448
Activo, no reclutando
Immunotherapy With Nivolumab and Ipilimumab Followed by Nivolumab or Nivolumab With Cabozantinib for Patients With Advanced Kidney Cancer, The PDIGREE Study NCT03793166
Activo, no reclutando
Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer NCT03233711
Activo, no reclutando
Testing the Role of DNA Released From Tumor Cells Into the Blood in Guiding the Use of Immunotherapy After Surgical Removal of the Bladder, Kidney, Ureter, and Urethra for Urothelial Cancer Treatment, MODERN Study NCT05987241
Reclutando
Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma NCT03937635
Reclutando
T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial NCT04457596
Activo, no reclutando
Testing MK-3475 (Pembrolizumab) as Adjuvant Therapy for Triple Receptor-Negative Breast Cancer NCT02954874
Activo, no reclutando
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO]) NCT04267848
Reclutando
Pegylated Liposomal Doxorubicin Hydrochloride With Atezolizumab and/or Bevacizumab in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer NCT02839707
Activo, no reclutandoResultados publicados
Estudio de pembrolizumab (MK-3475) más quimioterapia frente a placebo más quimioterapia para cáncer de mama localmente recurrente inoperable o metastásico HR+/HER2- (MK-3475-B49/KEYNOTE-B49) NCT04895358
Activo, no reclutando
A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy (KEEPsAKE 1) NCT03675308
Activo, no reclutandoResultados publicados
Dabrafenib and Trametinib Followed by Ipilimumab and Nivolumab or Ipilimumab and Nivolumab Followed by Dabrafenib and Trametinib in Treating Patients With Stage III-IV BRAFV600 Melanoma NCT02224781
Activo, no reclutandoResultados publicados
Nivolumab After Surgery and Chemotherapy in Treating Patients With Stage IB-IIIA Non-small Cell Lung Cancer (An ALCHEMIST Treatment Trial) (ANVIL) NCT02595944
Activo, no reclutando
Testing the Timing of Pembrolizumab Alone or With Chemotherapy as First Line Treatment and Maintenance in Non-small Cell Lung Cancer NCT03793179
Activo, no reclutando
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial Cancer NCT03914612
Activo, no reclutandoResultados publicados
Combination Chemotherapy With or Without Ganitumab in Treating Patients With Newly Diagnosed Metastatic Ewing Sarcoma NCT02306161
Activo, no reclutandoResultados publicados
Nivolumab and Ipilimumab in Treating Patients With Rare Tumors NCT02834013
Activo, no reclutando
A Comparison of Three Chemotherapy Regimens for the Treatment of Patients With Newly Diagnosed Mantle Cell Lymphoma NCT04115631
Activo, no reclutando